Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

E-ISSN： 1531-8249|77|3|425-435

ISSN： 0364-5134

Source： ANNALS OF NEUROLOGY, Vol.77, Iss.3, 2015-03, pp. : 425-435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 22, Iss. 3, 2015-03 ,pp. : 570-577

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging Therapies in Relapsing-Remitting Multiple Sclerosis

Reviews on Recent Clinical Trials, Vol. 5, Iss. 3, 2010-09 ,pp. : 179-188

Bentham Science Publishers

Access to resources Recommend Favorite

Teriflunomide for relapsing remitting multiple sclerosis

PRESCRIBER, Vol. 26, Iss. 18, 2015-09 ,pp. : 11-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis

By Namaka Mike Pollitt-Smith Merinda Gupta Aneri Klowak Meghann Vasconcelos Marcus Turcotte Dana Gong Yuewen Melanson Maria

Current Medical Research and Opinion, Vol. 22, Iss. 2, 2006-02 ,pp. : 223-239

Informa Healthcare

Access to resources Recommend Favorite

Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis

By de Sá J. Urbano G. Reis L.

Current Medical Research and Opinion, Vol. 26, Iss. 9, 2010-09 ,pp. : 2237-2242

Informa Healthcare

Access to resources Recommend Favorite